快速病原体检测对ICU疑似肺炎患者抗菌治疗的影响:随机、对照、开放标签可行性试验(IRISPAT-1)。
完整摘要 · 中文译文
背景:多重聚合酶链反应(mPCR)在重症监护环境中改善抗菌治疗和临床结局的证据有限。我们评估了快速mPCR对疑似肺炎的机械通气危重患者抗生素治疗的影响。 方法:IRISPAT-1是一项单中心、随机、对照、开放标签试验,旨在确定快速呼吸道病原体检测对疑似肺炎的机械通气危重患者抗生素治疗的可行性、安全性和潜在影响。疑似肺炎并在24小时内接受新抗生素治疗的机械通气成人患者被随机分配至标准治疗组或在标准治疗基础上使用BioFire® FilmArray®肺炎检测板的mPCR组(FA肺炎检测板组)。主要结局为至适当抗菌治疗的时间间隔(小时)。 结果:2024年7月7日至2025年10月4日期间,共随机纳入40例疑似肺炎的机械通气患者(20例=标准治疗,20例=FA肺炎检测板)。FA肺炎检测板组至适当抗生素治疗的中位(IQR)时间短于标准治疗组(7[5-16] vs. 72[41-140]小时,HR 3.3;95%CI [1.6, 6.6],p = 0.001)。FA肺炎检测板组90%(18/20)的患者遵循了治疗算法。两组在广谱抗生素使用、抗生素使用时长、无呼吸机天数或无血管升压药天数以及28天死亡率方面均无差异。 结论:快速mPCR与 在疑似肺炎的机械通气患者中,与标准治疗相比,高度依从抗生素算法缩短了至适当抗生素治疗的时间。 试验注册:于2024年6月23日在clinicaltrials.gov注册(NCT06478953)。
完整摘要 · 英文原文
BACKGROUND: Evidence that multiplex polymerase chain reaction (mPCR) improves antimicrobial therapy and clinical outcomes in the critical care setting is limited. We assessed the impact of rapid mPCR on antibiotic therapy in mechanically ventilated critically ill patients with suspected pneumonia. METHODS: IRISPAT-1 was a single center, randomized, controlled open-label trial designed to determine the feasibility, safety, and potential impact of rapid respiratory pathogen detection on antibiotic therapy in mechanically ventilated critically ill patients with suspected pneumonia. Mechanically ventilated adults with suspected pneumonia and treated with new antibiotics within 24 h were randomized to standard care or mPCR using BioFire® FilmArray® Pneumonia Panel in addition to standard care (FA Pneumonia Panel group). Primary outcome was time interval (hours) to appropriate antimicrobial therapy. RESULTS: Forty mechanically ventilated patients with suspected pneumonia were randomized (20 = standard care, 20 = FA Pneumonia Panel) between July 7, 2024 and October 4, 2025. Median (IQR) time to appropriate antibiotic therapy was shorter in the FA Pneumonia Panel group compared to the standard care group (7 [5-16] vs. 72 [41-140] hours, HR 3.3; 95%CI [1.6, 6.6], p = 0.001). Adherence to treatment algorithm was observed in 90% (18/20) of patients in the FA Pneumonia Panel group. There were no differences in use of broad-spectrum antibiotics, duration of antibiotics, ventilator free days or vasopressor free days and 28-day mortality between treatment groups. CONCLUSION: Rapid mPCR with high adherence to antibiotic algorithms shortened time to appropriate antibiotics compared to standard care in mechanically ventilated patients with suspected pneumonia. TRIAL REGISTRATION: Registered at clinicaltrials.gov (NCT06478953) on June 23, 2024.